Corporate Magazine 2012 - Boehringer Ingelheim

usiness year 2012the shareholders’ perspectiveThe patient’s partner – guided by people’s medical needsWe thereby succeed, together with the Board of Managing Directors and our employees,in making sustainable progress in the form of medicines and solutionsthat help people, giving physicians who provide treatment the opportunity of new,more effective and more efficacious therapies. We are guided by people’s medicalneeds, defined as needs for which there are today no adequate therapy options.We regard Boehringer Ingelheim as the patient‘s partner that provides innovativemedicines for better health.Passion for research and developmentPart of our own way is also that we have been able to achieve our innovations inhuman and veterinary pharmaceuticals from within, with our own network ofresearch and development sites, which has been successful for many years. Theefficient interplay between different strengths in each region is a key success factorhere. We feel that this strengthens our conviction that our investments and resultsin the form of innovative medications have far exceeded the industry average for along time.From our long corporate history as a research-driven pharmaceutical companywe know that innovations require decades, not just quarters. It takes over farmore than ten years before a new medication finds its way from the laboratory topatients. Part of the independence is also that researchers have been able to realisetheir innovations with the necessary long-term perspective, despite a cyclicalbusiness environment. At Boehringer Ingelheim investments in research anddevelopment also have an overarching emotionally binding component, as everyinnovation improves human health.The shareholders’ perspective7